據報國藥集團將向天壇生物注入新冠疫苗等資產 涉300億人幣
《路透》引述兩位消息人士報道,國藥集團計劃向天壇生物(600161.SH)注入300億元人民幣(約46億美元)資產,以將其快速增長的疫苗業務上市。
消息人士指,此舉有助於融資渠道多元化,國藥計劃在未來數周內開始將6間以疫苗為重點的生物製藥開發商(包括製造兩種新型肺炎疫苗的製造商)注入天壇生物,有關公司均由國藥集團下屬中國生物(CNBG)全資擁有或控股,而中國生物也持有天壇生物的50%股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.